Innovative Pharmaceutical Biotech Limited provided unaudited earnings guidance for the six months ended 30 September 2023. For the period, Group is expected to record a profit attributed to equity shareholders of the Company in the range between HKD 100 million and HKD 200 million, compared to the loss of approximately HKD 115.7 million for the same period in 2022, which was mainly attributable to the non-cash item resulted from the completion of the modification of convertible bonds during the period. The difference of the carrying value of the convertible bond and fair value of the liability component of the convertible bond at the completion was credited to the income statement.